Skip to Content

Nurix Therapeutics Inc Ordinary Shares NRIX

Morningstar Rating
$14.09 −0.58 (3.92%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

NRIX is trading within a range we consider fairly valued.
Price
$14.62
Fair Value
$39.12
Uncertainty
Extreme
1-Star Price
$61.31
5-Star Price
$5.56
Economic Moat
Xnmg
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NRIX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$14.66
Day Range
$14.0815.23
52-Week Range
$4.2318.01
Bid/Ask
$14.05 / $14.11
Market Cap
$694.99 Mil
Volume/Avg
495,148 / 1.0 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
9.88
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
284

Comparables

Valuation

Metric
NRIX
KPTI
IKNA
Price/Earnings (Normalized)
Price/Book Value
4.260.36
Price/Sales
9.880.855.79
Price/Cash Flow
Price/Earnings
NRIX
KPTI
IKNA

Financial Strength

Metric
NRIX
KPTI
IKNA
Quick Ratio
3.313.1412.35
Current Ratio
3.403.3712.58
Interest Coverage
−5.45
Quick Ratio
NRIX
KPTI
IKNA

Profitability

Metric
NRIX
KPTI
IKNA
Return on Assets (Normalized)
−30.46%−42.20%−32.53%
Return on Equity (Normalized)
−43.13%−38.49%
Return on Invested Capital (Normalized)
−45.00%−111.18%−36.66%
Return on Assets
NRIX
KPTI
IKNA
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRMdlzbkfcLvy$551.2 Bil
VRTX
Vertex Pharmaceuticals IncWhwmgxpwThhsfzk$101.9 Bil
REGN
Regeneron Pharmaceuticals IncHkwbwvfsZhvyfm$98.1 Bil
MRNA
Moderna IncDmxmrfckTxhsy$39.7 Bil
ARGX
argenx SE ADRZwyzqccVlcvq$22.1 Bil
BNTX
BioNTech SE ADRCtvnrzmDfp$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncVtjrxdhrRnbdc$18.6 Bil
BMRN
Biomarin Pharmaceutical IncRsjwtrvlJkvmhf$17.2 Bil
RPRX
Royalty Pharma PLC Class ACqgvxyjqyGftwm$12.3 Bil
INCY
Incyte CorpGljhnwvNtfwsv$11.9 Bil

Sponsor Center